{
  "drugid": "RxNorm:17128",
  "drugname": "lansoprazole",
  "guidelinename": "CYP2C19 and Proton Pump Inhibitors",
  "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/",
  "guidelinepharmgkbids": [
    "PA166219103",
    "PA166219301"
  ],
  "citations": [
    {
      "pmid": "32770672",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.",
      "authors": [
        "Lima John J",
        "Thomas Cameron D",
        "Barbarino Julia",
        "Desta Zeruesenay",
        "Van Driest Sara L",
        "El Rouby Nihal",
        "Johnson Julie A",
        "Cavallari Larisa H",
        "Shakhnovich Valentina",
        "Thacker David L",
        "Scott Stuart A",
        "Schwab Matthias",
        "Uppugunduri Chakradhara Rao S",
        "Formea Christine M",
        "Franciosi James P",
        "Sangkuhl Katrin",
        "Gaedigk Andrea",
        "Klein Teri E",
        "Gammal Roseann S",
        "Furuta Takahisa"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2020
    }
  ],
  "recommendations": [
    {
      "implications": {
        "CYP2C19": "Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs"
      },
      "drugrecommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C19": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Normal Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
      },
      "drugrecommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C19": "Rapid Metabolizer"
      },
      "activityscore": {
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Rapid Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
      },
      "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "activityscore": {
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "comments": "The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
      },
      "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C19": "Poor Metabolizer"
      },
      "activityscore": {
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "n/a"
      },
      "drugrecommendation": "No recommendation",
      "classification": "No Recommendation",
      "phenotypes": {
        "CYP2C19": "Indeterminate"
      },
      "activityscore": {
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Indeterminate"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
      },
      "drugrecommendation": "Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
      },
      "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "comments": "The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
      },
      "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    }
  ],
  "genes": [
    "CYP2C19"
  ],
  "notesonusage": null,
  "cpicVersion": "v1.26.0",
  "source": "CPIC"
}